Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Contraloid acetate in healthy subjects
NCT03944460Phase 1Completed
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRI-002 in Alzheimer's disease (AD) (10 arms). Primary endpoints: Assessment of safety and tolerability of Contraloid at 8 days, Area under curve (AUC) in plasma at 72 hours and 6 more. Started Apr 2018; status: completed.
02
Drugs
PRI-002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03944460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944460.